Our previous study showed that low-dose and long-term CSC treatment downregulates Smad3 protein expression, resulting in inhibition of TGF-β signaling and decrease in TGF-β-mediated tumor suppressor functions in NSCLC [15]. The gene discussed is SMAD3; the disease is non-small cell lung carcinoma.